Weight ManagementAlso known as: Imcivree, RM-493, MC4R agonist
Setmelanotide
First-in-class MC4R agonist (Imcivree) FDA-approved for rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency). Restores melanocortin signaling in patients with broken satiety pathways.
Half-Life
~11 hours
Dose Range
1-3 mg/day
Frequency
1× daily
Vial Sizes
10 mg
Mechanism of Action
Selective melanocortin-4 receptor (MC4R) agonist that restores the leptin-POMC-MC4R satiety pathway. Unlike broad melanocortin agonists (MT-II), setmelanotide has minimal MC1R activity, reducing skin darkening side effects.
Source: PMID: 32320060 (Phase 3 NEJM)
Dosing Protocol
| Typical Dose | 1-3 mg/day |
| Frequency | 1× daily |
| Half-Life | ~11 hours |
| Common Vial Sizes | 10 mg |
Reconstitution Example
Vial
10 mg
Water
2 mL
Concentration
5 mg/mL
Per Unit (100u syringe)
50 mcg
Dose of 1000 mcg = 20 units on a 100-unit insulin syringe
Dosing Quick Reference
Setmelanotide— Dosing Guide
Dose Range
1-3 mg/day
Half-Life
~11 hours
Frequency
1× daily
Route
Subcutaneous
10 mg vial
💧 2 mL BAC water|📐 5 mg/mL concentration|💉 50 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code